Arcus Biosciences (RCUS) Return on Capital Employed (2018 - 2026)

Arcus Biosciences' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 46.33% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 198.0% year-over-year to 46.33% in Q1 2026; TTM through Mar 2026 was 46.33%, a 198.0% decrease from a year earlier, with the FY2025 full-year figure at 42.26%, down 545.0% from the prior year.
• Return on Capital Employed improved to 46.33% in Q1 2026 per RCUS's latest filing, from 46.76% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 5.96% in Q3 2022 and bottomed at 47.5% in Q3 2025.
• The 5-year median for Return on Capital Employed is 30.72% (2024), against an average of 27.64%.
• Across the five-year window, Return on Capital Employed soared 4436 bps in 2022 and tumbled 3809 bps in 2023, its largest moves.
• Year by year, Return on Capital Employed stood at 24.27% in 2022, then tumbled by 46 bps to 35.45% in 2023, then increased by 7 bps to 33.03% in 2024, then slumped by 42 bps to 46.76% in 2025, then advanced by 1 bps to 46.33% in 2026.
• Per Business Quant, the three latest RCUS Return on Capital Employed figures stand at 46.33% (Q1 2026), 46.76% (Q4 2025), and 47.5% (Q3 2025).